Thrombosis and lung cancer

被引：1

作者：

Girard, P. ^{[1
]}

Raynaud, C. ^{[1
]}

Meyer, G. ^{[2
]}

Parent, F. ^{[3
]}

Besse, B. ^{[4
]}

机构：

[1] Inst Mutualiste Montsouris, Dept Thorac, F-75014 Paris, France

[2] Hop Europeen Georges Pompidou, Serv Pneumol, F-75015 Paris, France

[3] Hop Antoine Beclere, Serv Pneumol, F-92140 Clamart, France

[4] Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France

来源：

REVUE DE PNEUMOLOGIE CLINIQUE | 2008年 / 64卷 / 02期

关键词：

lung cancer; venous thromboembolism; treatment; prevention;

D O I：

10.1016/j.pneumo.2008.04.003

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

This relation is sometimes described as a double association: venous thromboembolism (VTE) can reveal cancer (so-called Trousseau syndrome), but cancer and its treatment are also risk factors for VTE. Lung cancer, frequent and serious, is one of the greatest purveyors of VTE, a disease that pneumologists and oncologists must often confront in diagnosis, prevention, and treatment. This article investigates the epidemiological, prevention, and treatment aspects of VTE in cancer patients, particularly those with lung cancer, but also discusses diagnostic specificities and, briefly, the possible antitumor effect of heparins. (C) 2008 Elsevier Masson SAS. Taus droits reserves.

引用

页码：85 / 91

页数：7

共 38 条

[1] High plasma d-dimer level is associated with decreased survival in patients with lung cancer [J].

Altiay, G. ;

Ciftci, A. ;

Demir, M. ;

Kocak, Z. ;

Sut, N. ;

Tabakoglu, E. ;

Hatipoglu, O. N. ;

Caglar, T. .

CLINICAL ONCOLOGY, 2007, 19 (07) :494-498

[2] A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer [J].

Altinbas, M ;

Coskun, HS ;

Er, O ;

Ozkan, M ;

Eser, B ;

Unal, A ;

Cetin, M ;

Soyuer, S .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1266-1271

[3] Screening for lung cancer - ACCP evidence-based clinical practice guidelines (2nd edition) [J].

Bach, Peter B. ;

Silvestri, Gerard A. ;

Hanger, Morgan ;

Jett, Jaines R. .

CHEST, 2007, 132 (03) :69S-77S

[4] Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. [J].

Bergqvist, D ;

Agnelli, G ;

Cohen, AT ;

Eldor, A ;

Nilsson, PE ;

Le Moigne-Amrani, A ;

Dietrich-Neto, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :975-980

[5] Malignancies, prothrombotic mutations, and the risk of venous thrombosis [J].

Blom, JW ;

Doggen, CJM ;

Osanto, S ;

Rosendaal, FR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :715-722

[6] Cancer and thrombosis: from molecular mechanisms to clinical presentations [J].

Buller, H. R. ;

Van Doormaal, F. F. ;

Van Sluis, G. L. ;

Kamphuisen, P. W. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 :246-254

[7] Antithrombotic therapy for venous thromboembolic disease [J].

Büller, HR ;

Agnelli, G ;

Hull, RD ;

Hyers, TA ;

Prins, AH ;

Raskob, GE .

CHEST, 2004, 126 (03) :401S-428S

[8]

Chew HK, 2006, ARCH INTERN MED, V166, P458

[9] Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period [J].

Deitcher, Steven R. ;

Kessler, Craig M. ;

Merli, Geno ;

Rigas, James R. ;

Lyons, Roger M. ;

Fareed, Jawed .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (04) :389-396

[10] D-dimer test in cancer patients with suspected acute pulmonary embolism [J].

Di Nisio, M ;

Sohne, M ;

Kamphuisen, PW ;

Büller, HR .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (06) :1239-1242

← 1 2 3 4 →